Oxolife

Oxolife is a small-sized clinical-stage company focused on the development of products in female fertility therapeutic area.

  • Stage Product In Development
  • Industry Chemicals and Chemical Products
  • Location Sant Quirze del Vallès, Spain
  • Currency EUR
  • Founded January 2013
  • Employees 2
  • Incorporation Type Other
  • Website oxolife.com

Company Summary

Oxolife is a small sized clinical stage company developing a unique pharmacological product, OXO-001, for embryo endometrial implantation and ovulation recovery in polycystic ovarian syndrome patients.
OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for fertility enhancement.
The Investor’s exit envisioned following the completion of the embryo implantation phase II in 2QY4

Team

  • Ignasi Canals Almazán
    CSO

    Biochemist from the UAB and a PhD in Molecular biology from the UB.
    6 years in biomedical research institutes (Fundació Clinic and IDIBAPS) developing his research thesis project leading a project to underly sodium tungstate mechanism of action in Obesity
    11 years in pharmaceutical industry (Bayer) as a scientific advisor in Women’s Health
    12 indexed papers
    Participated in 2 research programs funded by Spain/EU public programs

  • Agnès Arbat
    CEO / CMO

    MD UAB and is a Clinical Pharmacologist Specialist
    14 years of experience in pharmaceutical industry, leading Bayer’ Women’s Health and Cardiovascular Therapeutic Area Medical team (20FTE)
    10 indexed international papers
    More than 30 communications in international congresses
    More than 20 clinical trials leaded in WH area
    More than 10 product or new indication launched
    Mentoring Master Industria Farmacèutica I Biotecnologia UPF students

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free